Physician profile
Catherine Easter
NPI 1881647444
$8,393.68
in general payments reported to CMS, 2019-2025
31 companies · $2,527 in 2025
The $2,527 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,007 · 2022: $1,124 · 2023: $1,918 · 2024: $1,817 · 2025: $2,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,262.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,171.45 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,026.43 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $904.68 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $555.34 | 2021-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $535.32 | 2022-2025 | |
| Gilead Sciences, INC. | $381.98 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $332.26 | 2021-2023 | |
| Qol Medical, LLC | $289.35 | 2023-2025 | Sucraid, Sucraid |
| Celgene Corporation | $275.34 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $226.45 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $197.86 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $197.39 | 2024-2025 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $188.91 | 2023-2024 | Linzess |
| Aimmune Therapeutics, INC. | $152.64 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $151.46 | 2021-2023 | Injectafer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $125.28 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $106.83 | 2023-2025 | Ocaliva |
| Medtronic, INC. | $82.14 | 2025 | Gi Genius |
| Biofire Diagnostics, LLC | $68.09 | 2021 | |
| Braintree Laboratories, INC. | $65.16 | 2021-2023 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $55.28 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $46.66 | 2021-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $46.01 | 2022-2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $43.60 | 2021-2022 | |
| Celltrion USA INC. | $35.72 | 2025 | Vegzelma |
| Organon LLC | $32.69 | 2021-2022 | |
| Lilly USA, LLC | $24.94 | 2025 | Omvoh |
| Enterra Medical, INC. | $24.68 | 2023 | |
| Novo Nordisk INC | $21.15 | 2025 | Wegovy |
| Phadia US INC. | $14.79 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Easter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.